TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03923374

Intervention type: DRUG
Intervention: Subutex / Buprenorphine
Description: Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal & Neonatal MRI
Description: Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal & Neonatal MRI
Description: Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA/Genetic/Pharmacokenetic Blood Draws
Description: Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA/Genetic/Pharmacokenetic Blood Draws
Description: Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
Study: NCT03325985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic case management
Description: Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated,outpatient specialty palliative care
Description: In-person or telehealth palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
Study: NCT03755466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib, olumiant®
Description: To examine the effects of baricitinib in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib, olumiant®
Description: To examine the effects of baricitinib in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biologics
Description: To examine the effects of biologics in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biologics
Description: To examine the effects of biologics in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 MG [Xeljanz]
Description: To examine the effects of tofacitinib in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 MG [Xeljanz]
Description: To examine the effects of tofacitinib in RA patients
Study: NCT01471990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pituitary Adenylate Cyclase-Activating Polypeptide-38
Description: 10 pmol/kg/min over 20 mins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Intestinal Peptide
Description: 8 pmol/kg/min over 20 mins
Study: NCT00649688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
Description: 100/50mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopressor HCT® Tablets 100/50 mg
Description: 100/50mg, single dose fasting
Study: NCT05722301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Therapy
Description: The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG \> 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG \<40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
Study: NCT02578953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Test product
Description: Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Test product
Description: Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Reference product
Description: Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
Study: NCT05722301

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Testosterone Therapy
Description: For the sham procedure no pellets will be implanted.
Study: NCT00580840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: 400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
Study: NCT03014232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLED-f with HCO dialyzer
Description: Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLED-f with HF dialyzer
Description: Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
Study: NCT03541421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient involvement in administration of drugs
Description: The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
Study: NCT01338467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYEOP device
Description: Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
Study: NCT01290627

Intervention type: DEVICE
Intervention: Subjects implanted with DePuy LCS PS RP TKA
Description: Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)

Intervention type: DEVICE
Intervention: Subjects implanted with DePuy Sigma PS RP TKA
Description: Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
Study: NCT00119678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable, intravenous, 0 mg, every 28 days, 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
Study: NCT03014960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
Study: NCT02080052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted prostate biopsy
Study: NCT01631669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg Q 12 hours orally
Study: NCT03556215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eustachian tube dilatation device
Description: Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
Study: NCT00119678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Injectable, intravenous, 10 mg/kg, every 28 days
Study: NCT02578953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride-Reference product
Description: Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
Study: NCT04195555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study: NCT04327375

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT02100228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Oral, 2.5 or 5 mg BID
Study: NCT03556215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eustachian tube dilatation device
Description: Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eustachian tube dilatation device
Description: Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
Study: NCT04335305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: IV infusion over 30 minutes, 200 mg; single dose
Study: NCT00907452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan-prednisone-thalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide-dexamethasone
Study: NCT02319629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URSODIOL
Description: preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
Study: NCT02100228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral heparin and/or oral Vitamin K antagonist
Description: Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
Study: NCT04484545

Intervention type: DIAGNOSTIC_TEST
Intervention: Prognostic score
Description: Validation of scores of systemic inflammatory response
Study: NCT01964092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary employment schemes
Study: NCT03120117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough Test following Sling Surgery
Description: Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
Study: NCT00580840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
Study: NCT03556215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myringotomy
Description: Myringotomy will be performed using a standard procedure.
Study: NCT00580840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo (saline) administered as two injections every 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo (saline) administered as two injections every 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (saline) administered as two injections every 2 weeks
Study: NCT02659904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Less than 2 mm remaining palatal tissue thickness
Description: The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 mm or more remaining palatal tissue thickness
Description: The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
Study: NCT00107497

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study: NCT00830232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: closed-cell stent (Xact stent)
Description: Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-cell stent (Acculink carotid)
Description: Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device.
Study: NCT00757809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study: NCT01821144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt reduction
Description: Salt reduction

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No salt awareness education
Study: NCT03992066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral 150 mg tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Darbepoetin alfa
Description: solution intravenous injection

Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin alfa
Description: solution for intravenous injection
Study: NCT02501005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VT ablation
Description: Catheter ablation of ventricular tachycardia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VT ablation
Description: Catheter ablation of ventricular tachycardia
Study: NCT02815319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Steroid prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Steroid prophylaxis
Study: NCT01840046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5).
Study: NCT01893567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex Spray
Study: NCT00803491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem based learning
Description: Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rheumatology care.
Description: Individually base.
Study: NCT03981341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duavive (0.45 estrogens mg and 20 mg bazedoxifene)
Description: Drug given for 3 months in each participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duavive (0.45 estrogens mg and 20 mg bazedoxifene)
Description: Drug given for 3 months in each participant
Study: NCT02965326

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal swab; rectal biopsy.
Description: Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal swab; rectal biopsy.
Description: Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal swab; rectal biopsy.
Description: Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
Study: NCT03456947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
Study: NCT03169205

Intervention type: OTHER
Intervention: observation registry
Description: observation registry

Intervention type: OTHER
Intervention: observation registry
Description: observation registry

Intervention type: OTHER
Intervention: observation registry
Description: observation registry
Study: NCT02155205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 1500 mg telotristat etiprate (six 250 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg moxifloxacin (one 400 mg tablet)
Study: NCT03370549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARE intervention
Description: Group psychotherapy for Asian-American women

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AWARE intervention
Description: Group psychotherapy for Asian-American women
Study: NCT04462926

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11 PET/CT
Description: 1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
Study: NCT00841178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLT
Description: EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
Study: NCT00992771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: up to 1mg BID for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching varenicline, up to 1mg BID for 8 weeks
Study: NCT02335840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF-1
Description: In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF-2
Description: In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF-3
Description: In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DESC
Description: In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
Study: NCT02458469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 100 mg dose before bed-time
Study: NCT00107497

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study: NCT02458469

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill before bed-time
Study: NCT03613922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Manual Therapy
Description: Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
Study: NCT04056026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy